Literature DB >> 31873771

Preoperative biopsy and tumor recurrence of stage I adenocarcinoma of the lung.

Chien-Sheng Huang1,2, Po-Kuei Hsu3, Chun-Ku Chen4, Yi-Chen Yeh5, Hui-Shan Chen6, Mei-Han Wu4, Teh-Ying Chou5, Wen-Hu Hsu3, Chun-Che Shih7,8, Biing-Shiun Huang3.   

Abstract

PURPOSE: To evaluate whether preoperative biopsy affects the outcomes of patients undergoing at least lobectomy for stage I lung adenocarcinoma.
METHODS: We reviewed the medical records of patients who underwent surgery for stage I lung adenocarcinoma between 2006 and 2013. Tumor recurrence and survival were compared between patients who underwent preoperative biopsy, including computed tomographic-guided needle biopsy and transbronchial biopsy, and those who underwent intraoperative frozen section.
RESULTS: Among 509 patients, 229 patients (44.9%) underwent preoperative biopsy and 280 patients had lung adenocarcinoma diagnosed by intraoperative frozen section (reference group). Recurrence developed in 65 (12.8%) patients within a median follow-up period of 54.4 months. Multivariate analysis demonstrated that preoperative biopsy (OR 1.97, p = 0.045), radiological solid appearance (OR 5.43, p < 0.001), and angiolymphatic invasion (OR 2.48, p = 0.010) were independent predictors of recurrence. In the overall cohort, preoperative biopsy appeared to worsen 5-year disease-free and overall survival significantly (76.6% vs. 93.0%, p < 0.001; and 83.8% vs. 94.5%, p = 0.002, respectively) compared with the reference group. After propensity matching, multivariable logistic regression still identified preoperative biopsy as an independent predictor of overall recurrence (OR 2.21, p = 0.048) after adjusting for tumor characteristics.
CONCLUSION: Preoperative biopsy might be considered a prognosticator of recurrence of stage I adenocarcinoma of the lungs in patients who undergo at least anatomic lobectomy without postoperative adjuvant chemotherapy.

Entities:  

Keywords:  Disease-free survival; Early-stage lung cancer; Preoperative biopsy; Tumor recurrence

Mesh:

Year:  2019        PMID: 31873771     DOI: 10.1007/s00595-019-01941-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  3 in total

1.  Significance of preoperative biopsy in radiological solid-dominant clinical stage I non-small-cell lung cancer.

Authors:  Chien-Sheng Huang; Hung-Che Chien; Chun-Ku Chen; Yi-Chen Yeh; Po-Kuei Hsu; Hui-Shan Chen; Chih-Cheng Hsieh; Han-Shui Hsu; Biing-Shiun Huang; Chun-Che Shih
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-04-19

2.  Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma.

Authors:  Chia Liu; Lei-Chi Wang; Hui-Shan Chen; Yi-Chen Yeh; Po-Kuei Hsu; Chien-Sheng Huang; Chih-Cheng Hsieh; Han-Shui Hsu
Journal:  Thorac Cancer       Date:  2022-06-09       Impact factor: 3.223

3.  Effect of intraoperative needle biopsy on the survival of nonsmall cell lung cancer patients: a propensity score matching analysis.

Authors:  Mizuki Morota; Masaaki Nagano; Naohiro Ijiri; Nobuyuki Yoshiyasu; Yoshikazu Shinohara; Yuya Nobori; Hirokazu Yamaguchi; Shun Kawashima; Masahiro Yanagiya; Chihiro Konoeda; Kentaro Kitano; Masaaki Sato; Jun Nakajima
Journal:  Surg Today       Date:  2022-03-03       Impact factor: 2.540

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.